Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Wai Yuen Tong Medicine Holdings Limited ( (HK:0897) ).
Wai Yuen Tong Medicine Holdings Limited announced its final results for the year ended 31 March 2025, reporting a decrease in revenue by 4.9% to HK$745.3 million from continuing operations. Despite the revenue decline, the company saw a significant improvement in profitability, with profit for the year increasing by 77.5% to HK$7.1 million, and earnings per share rising by 148.5%. The company’s net assets value and cash equivalents saw a decline, but the gearing ratio improved slightly. These results indicate a positive shift in the company’s financial performance, potentially enhancing its market position and offering a more favorable outlook for stakeholders.
More about Wai Yuen Tong Medicine Holdings Limited
Wai Yuen Tong Medicine Holdings Limited is a company incorporated in Bermuda with limited liability, primarily engaged in the pharmaceutical industry. It focuses on the production and sale of traditional Chinese medicine and health products.
Average Trading Volume: 473,710
Technical Sentiment Signal: Buy
Current Market Cap: HK$376.9M
For detailed information about 0897 stock, go to TipRanks’ Stock Analysis page.